Blasts from patients with myelodysplastic syndrome-related AML (AML-MDS) appear to express CD25 more frequently compared with de novo AML patients,7 but although late-stage MDS is typically chemoresistant, the prognostic relevance of CD25 has not been investigated yet. Here, IL2RA is linked to myelodysplastic syndrome.